MedPath

Western History Collection

Western History Collection logo
🇺🇸United States
Ownership
Private
Established
1890-01-01
Employees
10K
Market Cap
-
Website
http://www.ou.edu

Clinical Trials

392

Active:21
Completed:200

Trial Phases

6 Phases

Early Phase 1:16
Phase 1:31
Phase 2:40
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (326 trials with phase data)• Click on a phase to view related trials

Not Applicable
210 (64.4%)
Phase 2
40 (12.3%)
Phase 1
31 (9.5%)
Phase 4
19 (5.8%)
Early Phase 1
16 (4.9%)
Phase 3
10 (3.1%)

Improving Rates of Diagnostic Colonoscopy in Native Americans

Not Applicable
Not yet recruiting
Conditions
CRC Screening
CRC (Colorectal Cancer)
First Posted Date
2025-08-11
Last Posted Date
2025-08-11
Lead Sponsor
University of Oklahoma
Target Recruit Count
164
Registration Number
NCT07115875
Locations
🇺🇸

TSET Health Promotion Research Center, Oklahoma City, Oklahoma, United States

Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation

Not Applicable
Not yet recruiting
Conditions
Smoking Cessation
Interventions
Drug: Varenicline (VAR)
Drug: Nicotine lozenge (NRT)
Behavioral: Smartphone intervention with adherence components (ADHERE)
Behavioral: Telephone Counseling
Behavioral: Smartphone intervention without adherence components (NO ADHERE)
First Posted Date
2025-08-01
Last Posted Date
2025-08-01
Lead Sponsor
University of Oklahoma
Target Recruit Count
496
Registration Number
NCT07099638
Locations
🇺🇸

TSET Health Promotion Research Center, Oklahoma City, Oklahoma, United States

Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain

Not Applicable
Not yet recruiting
Conditions
Smoking Cessation Intervention
Pain
Smoking (Tobacco) Addiction
First Posted Date
2025-07-23
Last Posted Date
2025-07-23
Lead Sponsor
University of Oklahoma
Target Recruit Count
150
Registration Number
NCT07080788
Locations
🇺🇸

University of Oklahoma - Schusterman Center, Tulsa, Oklahoma, United States

Connect2Care: Prostate Cancer Education and Screenings for African American Men

Not Applicable
Not yet recruiting
Conditions
Prostate Cancer
Health Behavior
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
University of Oklahoma
Target Recruit Count
466
Registration Number
NCT07055165
Locations
🇺🇸

TSET Health Promotion Research Center, Oklahoma City, Oklahoma, United States

Improving Sleep, Fatigue, Activity & Quality of Life in Cancer Survivors Via a Transdiagnostic Intervention

Not Applicable
Not yet recruiting
Conditions
Cancer Survivors
First Posted Date
2025-06-17
Last Posted Date
2025-07-24
Lead Sponsor
University of Oklahoma
Target Recruit Count
12
Registration Number
NCT07023783
Locations
🇺🇸

University of Oklahoma College of Allied Health, Oklahoma City, Oklahoma, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 79
  • Next

News

University of Oklahoma Researchers Unlock Amylin Receptor Mechanisms for Next-Generation Obesity Drugs

University of Oklahoma researchers published breakthrough findings in Science Signaling revealing new understanding of how amylin receptors function, providing crucial insights for obesity drug development.

Smart-T Smoking Cessation App Shows Nearly Double Quit Rates in Low-Income Adults

University of Oklahoma researchers developed Smart-T, a real-time adaptive smartphone app that nearly doubled smoking cessation rates compared to a static app in a clinical trial of 454 low-income smokers.

Novel Hafnium-Based Treatment Trial Launches for Cisplatin-Ineligible Head and Neck Cancer Patients

International researchers launch NANORAY-312 trial investigating hafnium metal therapy combined with radiation as a novel treatment approach for head and neck cancer patients unsuitable for cisplatin treatment.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.